107 related articles for article (PubMed ID: 1643743)
21. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
22. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells.
Kaizer H; Stuart RK; Brookmeyer R; Beschorner WE; Braine HG; Burns WH; Fuller DJ; Korbling M; Mangan KF; Saral R
Blood; 1985 Jun; 65(6):1504-10. PubMed ID: 3888315
[TBL] [Abstract][Full Text] [Related]
23. In vitro effects of etoposide purging on natural killer cells.
Silva MR; Ascensao JL
J Hematother; 1995 Dec; 4(6):563-70. PubMed ID: 8846017
[TBL] [Abstract][Full Text] [Related]
24. Lytic activity of IL-2 and IL-12 stimulated NK cells against HOS osteosarcoma cell line.
Mariani E; Tarozzi A; Meneghetti A; Tadolini M; Facchini A
Boll Soc Ital Biol Sper; 1996; 72(1-2):21-7. PubMed ID: 8868111
[TBL] [Abstract][Full Text] [Related]
25. Characterization of natural killer cells cultured from human bone marrow cells.
Yoda Y; Kawakami Z; Shibuya A; Abe T
Exp Hematol; 1988 Sep; 16(8):712-7. PubMed ID: 3042444
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
[TBL] [Abstract][Full Text] [Related]
27. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
[TBL] [Abstract][Full Text] [Related]
28. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells.
Uchida A; Yagita M; Sugiyama H; Hoshino T; Moore M
Int J Cancer; 1984 Sep; 34(3):375-81. PubMed ID: 6592156
[TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
[TBL] [Abstract][Full Text] [Related]
30. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
Wiltrout RH; Pilaro AM; Gruys ME; Talmadge JE; Longo DL; Ortaldo JR; Reynolds CW
J Immunol; 1989 Jul; 143(1):372-8. PubMed ID: 2732472
[TBL] [Abstract][Full Text] [Related]
32. The effect of cyclophosphamide derivatives on cellular cytotoxicity (NK, ADCC) in vitro.
Wasik M; Rychlik G; Górski A
Arch Immunol Ther Exp (Warsz); 1990; 38(3-4):259-65. PubMed ID: 2102658
[TBL] [Abstract][Full Text] [Related]
33. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood.
Mills KC; Gross TG; Varney ML; Heimann DG; Reed EC; Kessinger A; Talmadge JE
Bone Marrow Transplant; 1996 Jul; 18(1):53-61. PubMed ID: 8831996
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
Casorati G; Locatelli F; Pagani S; Garavaglia C; Montini E; Lisini D; Turin I; Rossi F; Dellabona P; Maccario R; Montagna D
Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
[TBL] [Abstract][Full Text] [Related]
35. Population dynamics of natural killer cells and T lymphocytes in murine spleen and bone marrow during the development of erythroleukemia: the effect of indomethacin.
Miller SC; Christopher FL; Dussault I
Nat Immun; 1992; 11(2):78-91. PubMed ID: 1498521
[TBL] [Abstract][Full Text] [Related]
36. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
37. Augmentation of human natural killer cell activity by cyclophosphamide in vitro.
Sharma B; Vaziri ND
Cancer Res; 1984 Aug; 44(8):3258-61. PubMed ID: 6589041
[TBL] [Abstract][Full Text] [Related]
38. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.
Lotzová E; Savary CA; Herberman RB
J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cells in the blood and bone marrow of the rhesus monkey.
Gengozian N; Longley RE; Filler J; Good RA
Cell Immunol; 1986 Aug; 101(1):24-38. PubMed ID: 3742605
[TBL] [Abstract][Full Text] [Related]
40. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
